In a double-blind pilot RCT of 72 adults with acute severe ulcerative colitis on IV corticosteroids, day-7 clinical response was similar with tofacitinib 20 vs 30 mg/day (91.7% vs 86.1%; RR 1.06, P=.46). 90-day event-free survival was also similar; no VTE or MACE.
RCTn = 72
Singh et al. Tofacitinib 20 vs 30 mg in acute severe ulcerative colitis: a double-blind randomized controlled trial